<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00490971</url>
  </required_header>
  <id_info>
    <org_study_id>CR010825</org_study_id>
    <secondary_id>R076477BIM3004</secondary_id>
    <nct_id>NCT00490971</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder</brief_title>
  <official_title>A Randomized, Double-Blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Extended-Release Paliperidone as Maintenance Treatment After an Acute Manic or Mixed Episode Associated With Bipolar I Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness and safety of oral
      extended-release (ER) paliperidone compared with placebo in the prevention of the recurrence
      of mood symptoms in patients with Bipolar I Disorder who initially respond to treatment of an
      acute manic or mixed episode with paliperidone ER. Olanzapine was included as an active
      control arm, although the study is not designed to allow for a direct comparison of
      olanzapine with paliperidone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (patients are assigned different treatments based on chance),
      double-blind (neither the patient nor the physician knows whether drug or placebo is being
      taken), active- and placebo-controlled, parallel-group, multicenter study to evaluate the
      efficacy (effectiveness) and safety of paliperidone ER relative to placebo in the prevention
      of recurrent mood symptoms associated with Bipolar I Disorder.

      There are 5 phases in this study: a screening phase (lasting up to 7 days) to establish a
      subject's eligibility for the study,; a 3-week double-blind acute treatment phase to treat
      the acute or manic episode; a 12-week double-blind treatment continuation phase to establish
      a patient's clinical stability,; a double-blind treatment maintenance phase to measure the
      time to symptom recurrence that will last until the patient experiences a recurrence,; and a
      follow-up phase consisting of a visit approximately 1 week after the last study visit. All
      antipsychotic drugs and all mood stabilizers other than study drug must be discontinued
      before the first study drug administration.

      Hospitalization is required for at least the first 7 days of the acute treatment phase. At
      the beginning of the acute treatment phase, patients will be randomly assigned to receive ER
      paliperidone or olanzapine in a 4:1 ratio. Patients in the ER paliperidone group who have a
      clinical response at the end of the acute treatment phase, remain clinically stable
      throughout the continuation phase, and achieve remission for each of the last 3 weeks of the
      continuation phase will again be randomly assigned: they will be assigned in a 1:1 ratio to
      receive ER paliperidone or placebo in the maintenance phase. Patients in the olanzapine
      treatment group who fulfill the same criteria will continue receiving double-blind treatment
      with olanzapine in the maintenance phase.

      Measures of efficacy used are the Young Mania Rating Scale (YMRS), Montgomery-Åsberg
      Depression Rating Scale (MADRS), Clinical Global Impression - Bipolar Disorder - Severity of
      Illness Scale (CGI-BP-S), Global Assessment of Functioning (GAF), the Short Form-36 to
      measure health-related functional status, and the sleep visual analog scale (VAS).

      Safety evaluations include monitoring of adverse events, clinical laboratory tests (including
      urine pregnancy testing and hemoglobin A1c), 12-lead ECG, vital signs measurements,
      measurement of orthostatic changes in pulse and blood pressure, physical examinations
      (including height, body weight, and waist circumference), and monitoring of extrapyramidal
      symptoms using the Abnormal Involuntary Movement Scale (AIMS), the Barnes Akathisia Rating
      Scale (BARS), and the Simpson Angus Scale (SAS). In addition, the Scale for Suicidal Ideation
      will be administered to assess suicidality.

      The primary hypothesis for this study is that, during the long-term treatment of patients
      with Bipolar I Disorder who maintain clinical stability after an acute manic or mixed
      episode, ER paliperidone is superior to placebo in delaying the time to recurrence of any
      mood symptoms associated with Bipolar I Disorder. Patients begin the acute treatment phase at
      6.0 mg/day of oral ER paliperidone or 10 mg/day of oral olanzapine. Dosages may be adjusted,
      as needed, between 3 to 12 mg/day of ER paliperidone or 5 to 20 mg/day of olanzapine, through
      the end of the continuation phase. Then, in the maintenance phase, patients receive the
      dosage of ER paliperidone (or ER paliperidone placebo) or olanzapine reached at the end of
      the continuation phase. They remain on those dosages until the end of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Recurrence of Any Mood Symptoms (Manic or Depressive) Associated With Bipolar I Disorder</measure>
    <time_frame>Date of randomization into the maintenance phase until the first occurrence of recurrence of any symptoms or discontinuation from the study, assessed over a period of 41 months.</time_frame>
    <description>Time to first recurrence of any mood symptoms (ie, manic or depressive) associated with bipolar I disorder during the maintenance phase, after maintaining clinical stability during continued treatment with paliperidone ER over a period of 15 weeks. The time period was from occurrence of acute manic or mixed episode to Week 15. This outcome was measured using combination of various scales, hospitalization for any mood symptoms, use of any medicines for an mood episode and clinical events suggestive of recurrent mood episode associated with bipolar I disorder.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Recurrence of Manic Symptoms Associated With Bipolar I Disorder</measure>
    <time_frame>Date of randomization into the maintenance phase until the first occurrence of recurrence of manic symptoms or discontinuation from the study, assessed over a period of 41 months.</time_frame>
    <description>This was the key secondary efficacy end-point. Pali/Pali and Pali/Placebo were compared with each other with respect to time to recurrence of manic symptoms. The criterias used for this analysis were similar to criterias used for primary analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Recurrence of Depressive Symptoms Associated With Bipolar I Disorder</measure>
    <time_frame>Date of randomization into the maintenance phase until the first occurrence of recurrence of depressive symptoms or discontinuation from the study, assessed over a period of 41 months.</time_frame>
    <description>Pali/Pali and Pali/Placebo were compared with each other with respect to time to recurrence of depressive symptoms. The criterias used for this analysis were similar to criterias used for primary analysis.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Young Mania Rating Scale (YMRS): Change From Baseline</measure>
    <time_frame>From 1st randomization into acute phase to end of acute/continuation phase (ie, up to 15 weeks after 1st randomization), or from randomization into maintenance (MA) phase to the end of MA phase (ie, up to 175 weeks (or 41 months) after 2nd randomization).</time_frame>
    <description>This is method by which condition of patient suffering with mania is checked. In this scale patient's condition is assessed using 11 items. A severity rating is assigned to each of 11 items based on the how subject feels of his or her condition and the physicians observation of patients behavior. The range of the scale is 0 to 60. A higher score indicates a more severe condition. Change from baseline (Day 105) in the double‑blind maintenance phase to the last postbaseline assessment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>From 1st randomization into acute phase to end of acute/continuation phase (ie, up to 15 weeks after 1st randomization), or from randomization into maintenance (MA) phase to the end of MA phase (ie, up to 175 weeks (or 41 months) after 2nd randomization).</time_frame>
    <description>The MADRS consists of 10 items covering all the important complaints which patient with depression have (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts). Item is scored from 0 (normal) to 6 (severe). Total score (0 to 60) is calculated by adding the scores of all 10 items. A higher score represents a more severe condition. Negative Change in Score Indicates Improvement.</description>
  </other_outcome>
  <other_outcome>
    <measure>Global Assessment of Functioning (GAF): Change From Baseline</measure>
    <time_frame>From 1st randomization into acute phase to end of acute/continuation phase (ie, up to 15 weeks after 1st randomization), or from randomization into maintenance (MA) phase to the end of MA phase (ie, up to 175 weeks (or 41 months) after 2nd randomization).</time_frame>
    <description>This scale is used when the clinical progress of a subject needs to be assessed in global terms, using a single measure. The GAF scale is rated with respect to psychological, social, and occupational functioning at the time of the assessment only. A higher score indicates a better functioning, with an overall range from 1 to 100. Positive Change in Score Indicates Improvement.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Global Impression - Bipolar Disorder - Severity of Illness (CGI-BP-S): Change From Baseline</measure>
    <time_frame>From 1st randomization into acute phase to end of acute/continuation phase (ie, up to 15 weeks after 1st randomization), or from randomization into maintenance (MA) phase to the end of MA phase (ie, up to 175 weeks (or 41 months) after 2nd randomization).</time_frame>
    <description>The CGI-BP-S rating scale is used to rate the severity of bipolar disorder, including both depressed and manic components, on a 7-point scale ranging from 1 (not ill) to 7 (very severely ill). This scale permits a global evaluation of the subject's bipolar condition at a given time. Negative Change in Score Indicates Improvement.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">768</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Paliperidone ER</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Once daily in dose range of 5 to 20 mg/day for 15 weeks, then until recurrence</description>
    <arm_group_label>Olanzapine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paliperidone ER</intervention_name>
    <description>Once daily in dose range of 3 to 12 mg/day for 15 weeks, then until recurrence</description>
    <arm_group_label>Paliperidone ER</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once daily until recurrence (only after initial 15 weeks on paliperidone ER)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition)
             criteria for Bipolar I Disorder Most Recent Episode Manic or Mixed (with or without
             psychotic features)

          -  have a history of at least 2 previously documented mood episodes associated with
             Bipolar I Disorder (1 of which must be a manic or mixed episode) that required medical
             treatment within the past 3 years

          -  a total score of at least 20 on the YMRS at screening and at Day 1 of the study.

        Exclusion Criteria:

          -  Meet DSM-IV criteria for any type of episode associated with bipolar disorder other
             than Bipolar I Disorder Most Recent Episode Manic or Mixed

          -  Meet DSM-IV criteria for rapid cycling

          -  Meet DSM-IV criteria for schizoaffective disorder

          -  Known or suspected borderline or antisocial personality disorder

          -  be, in the opinion of the investigator, at significant immediate risk for suicidal or
             violent behavior during the course of the study based on current status or prior
             history (e.g., suicide attempts during previous episodes).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L. C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Willingboro</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyndhurst</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bulgaria</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Radnevo N/A</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baoding</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Xi'An</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Jose</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San José</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Casablanca</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manouba</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chemnitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calicut</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coimbatore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ludhiana</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varanasi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Panama Panama</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Panama</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk N/A</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow N/A</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leszno N/A</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Skape</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Swiecie Poland</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torun N/A</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tuszyn N/A</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tg Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krasnodar N/A</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nizny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perm</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Smolensk Region N/A</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yaroslavl N/A</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beograd</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gornja Toponica</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novi Knezevac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durban Kn</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manisa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lvov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>China</country>
    <country>Costa Rica</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Malaysia</country>
    <country>Panama</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>South Africa</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Former Serbia and Montenegro</country>
    <country>Morocco</country>
    <country>Tunisia</country>
  </removed_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2007</study_first_submitted>
  <study_first_submitted_qc>June 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2007</study_first_posted>
  <results_first_submitted>April 26, 2011</results_first_submitted>
  <results_first_submitted_qc>January 31, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 5, 2012</results_first_posted>
  <last_update_submitted>March 25, 2015</last_update_submitted>
  <last_update_submitted_qc>March 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bipolar Disorder</keyword>
  <keyword>Mania</keyword>
  <keyword>Depression</keyword>
  <keyword>Manic-Depressive Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Paliperidone Palmitate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The double-blind (ie, niether physician nor patient knows the treatment that the patient receives) study has 15-week acute/continuation phase followed by variable-duration maintenance phase (lasting until patient had recurrence or discontinued treatment) to assess effect of paliperidone on maintenance of remission of Bipolar I Disorder</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Paliperidone Extented Release (ER)</title>
          <description>Acute and continuation period. Paliperidone ER: Oral tablet, 3 mg/day to 12 mg/day, Once daily.</description>
        </group>
        <group group_id="P2">
          <title>Olanzapine</title>
          <description>Acute and continuation period. Olanzapine: Oral tablet, 5 mg/day to 20 mg/day, Once daily.</description>
        </group>
        <group group_id="P3">
          <title>Pali/Placebo</title>
          <description>Maintenance period. Placebo (Paliperidone in the acute and continuation period).</description>
        </group>
        <group group_id="P4">
          <title>Pali/Pali</title>
          <description>Maintenance period. Paliperidone ER: Oral tablet, 3 mg/day to 12 mg/day, Once daily (Paliperidone in the acute and continuation period)</description>
        </group>
        <group group_id="P5">
          <title>Olan/Olan</title>
          <description>Maintenance period. Olanzapine Oral tablet, 5 mg/day to 20 mg/day, Once daily (Olanzapine in the acute and continuation period)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Acute/Continuation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="614">617 participants were assigned to paliperidone, out of which 614 took the study medication.</participants>
                <participants group_id="P2" count="148">149 participants were assigned to paliperidone, out of which 148 took the study medication.</participants>
                <participants group_id="P3" count="0">&quot;0&quot; indicates this group is not relevant to acute and continuation period.</participants>
                <participants group_id="P4" count="0">&quot;0&quot; indicates this group is not relevant to acute and continuation period.</participants>
                <participants group_id="P5" count="0">&quot;0&quot; indicates this group is not relevant to acute and continuation period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="308"/>
                <participants group_id="P2" count="86"/>
                <participants group_id="P3" count="0">&quot;0&quot; indicates this group is not relevant to acute and continuation period.</participants>
                <participants group_id="P4" count="0">&quot;0&quot; indicates this group is not relevant to acute and continuation period.</participants>
                <participants group_id="P5" count="0">&quot;0&quot; indicates this group is not relevant to acute and continuation period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="306"/>
                <participants group_id="P2" count="62"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">&quot;0&quot; indicates this group is not relevant to maintenance period.</participants>
                <participants group_id="P2" count="0">&quot;0&quot; indicates this group is not relevant to maintenance period.</participants>
                <participants group_id="P3" count="147">148 participants were assigned to pali/placebo, out of which 147 took the study medication.</participants>
                <participants group_id="P4" count="149">152 participants were assigned to pali/pali, out of which 149 took the study medication.</participants>
                <participants group_id="P5" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">&quot;0&quot; indicates this group is not relevant to maintenance period.</participants>
                <participants group_id="P2" count="0">&quot;0&quot; indicates this group is not relevant to maintenance period.</participants>
                <participants group_id="P3" count="96"/>
                <participants group_id="P4" count="96"/>
                <participants group_id="P5" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="53"/>
                <participants group_id="P5" count="39"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Paliperidone ER</title>
          <description>Acute and continuation period. Paliperidone ER: Oral tablet, 3 mg/day to 12 mg/day, Once daily.</description>
        </group>
        <group group_id="B2">
          <title>Olanzapine</title>
          <description>Acute and continuation period. Olanzapine: Oral tablet, 5 mg/day to 20 mg/day, Once daily.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="614"/>
            <count group_id="B2" value="148"/>
            <count group_id="B3" value="762"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="606"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="751"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.7" spread="11.93"/>
                    <measurement group_id="B2" value="39.2" spread="11.49"/>
                    <measurement group_id="B3" value="39.6" spread="11.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="310"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="304"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eastern Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>European Union</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Costa Rica</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morocco</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Panama</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tunisia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AgeCategorical</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18-25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>26-50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="378"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>51-65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Recurrence of Any Mood Symptoms (Manic or Depressive) Associated With Bipolar I Disorder</title>
        <description>Time to first recurrence of any mood symptoms (ie, manic or depressive) associated with bipolar I disorder during the maintenance phase, after maintaining clinical stability during continued treatment with paliperidone ER over a period of 15 weeks. The time period was from occurrence of acute manic or mixed episode to Week 15. This outcome was measured using combination of various scales, hospitalization for any mood symptoms, use of any medicines for an mood episode and clinical events suggestive of recurrent mood episode associated with bipolar I disorder.</description>
        <time_frame>Date of randomization into the maintenance phase until the first occurrence of recurrence of any symptoms or discontinuation from the study, assessed over a period of 41 months.</time_frame>
        <population>Intent-to-treat analysis set (ITT) in maintenance (MA) phase, which included participants who entered the MA phase and took at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone ER</title>
            <description>Acute and continuation period. Paliperidone ER: Oral tablet, 3 mg/day to 12 mg/day, Once daily.</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>Acute and continuation period. Olanzapine: Oral tablet, 5 mg/day to 20 mg/day, Once daily.</description>
          </group>
          <group group_id="O3">
            <title>Pali/Placebo</title>
            <description>Maintenance period. Placebo (Paliperidone in the acute and continuation period).</description>
          </group>
          <group group_id="O4">
            <title>Pali/Pali</title>
            <description>Maintenance period. Paliperidone ER: Oral tablet, 3 mg/day to 12 mg/day, Once daily (Paliperidone in the acute and continuation period)</description>
          </group>
          <group group_id="O5">
            <title>Olan/Olan</title>
            <description>Maintenance period. Olanzapine Oral tablet, 5 mg/day to 20 mg/day, Once daily (Olanzapine in the acute and continuation period)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Recurrence of Any Mood Symptoms (Manic or Depressive) Associated With Bipolar I Disorder</title>
          <description>Time to first recurrence of any mood symptoms (ie, manic or depressive) associated with bipolar I disorder during the maintenance phase, after maintaining clinical stability during continued treatment with paliperidone ER over a period of 15 weeks. The time period was from occurrence of acute manic or mixed episode to Week 15. This outcome was measured using combination of various scales, hospitalization for any mood symptoms, use of any medicines for an mood episode and clinical events suggestive of recurrent mood episode associated with bipolar I disorder.</description>
          <population>Intent-to-treat analysis set (ITT) in maintenance (MA) phase, which included participants who entered the MA phase and took at least 1 dose of study medication.</population>
          <units>Days</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="144"/>
                <count group_id="O4" value="146"/>
                <count group_id="O5" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>25% Quantile of Time to Recurrence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="85.0" lower_limit="72.0" upper_limit="141.0"/>
                    <measurement group_id="O4" value="140.0" lower_limit="72.0" upper_limit="274.0"/>
                    <measurement group_id="O5" value="541" lower_limit="386.0">There were 23% of the subjects in Olan/Olan treatment group who reported recurrence. Hence 25% quantile of time to recurrence was not observed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median Time to Recurrence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="283.0" lower_limit="203.0" upper_limit="531.0"/>
                    <measurement group_id="O4" value="558.0" lower_limit="401.0" upper_limit="804.0"/>
                    <measurement group_id="O5" value="NA">There were 23% of the subjects in Olan/Olan treatment group who reported recurrence. Hence median time to recurrence was not observed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference between Pali/Pali and Pali/Placebo in the time to recurrence of any mood symptoms related to bipolar I disorder. An interim analysis was performed when approximately 85% of the required number of recurrences were reported in Pali/Pali and Pali/Placebo treatment groups. A flexible group-sequential approach was adopted. The general family of alpha spending function based on the rho-family with rho=2.5 at overall type I error of 0.025 (1-sided) was employed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <p_value_desc>The two treatment groups were compared using a weighted z-statistic based on rho-family of alpha spending function at information fraction of 85.0% at interim analysis analysis (rho=2.5) at 0.025 (1-sided) level. One-sided alpha at final was 0.0195.</p_value_desc>
            <method>Weighted Z- test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Recurrence of Manic Symptoms Associated With Bipolar I Disorder</title>
        <description>This was the key secondary efficacy end-point. Pali/Pali and Pali/Placebo were compared with each other with respect to time to recurrence of manic symptoms. The criterias used for this analysis were similar to criterias used for primary analysis.</description>
        <time_frame>Date of randomization into the maintenance phase until the first occurrence of recurrence of manic symptoms or discontinuation from the study, assessed over a period of 41 months.</time_frame>
        <population>Intent-to-treat analysis set in MA phase, which included participants who entered the MA phase and took at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone ER</title>
            <description>Acute and continuation period. Paliperidone ER: Oral tablet, 3 mg/day to 12 mg/day, Once daily.</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>Acute and continuation period. Olanzapine: Oral tablet, 5 mg/day to 20 mg/day, Once daily.</description>
          </group>
          <group group_id="O3">
            <title>Pali/Placebo</title>
            <description>Maintenance period. Placebo (Paliperidone in the acute and continuation period).</description>
          </group>
          <group group_id="O4">
            <title>Pali/Pali</title>
            <description>Maintenance period. Paliperidone ER: Oral tablet, 3 mg/day to 12 mg/day, Once daily (Paliperidone in the acute and continuation period)</description>
          </group>
          <group group_id="O5">
            <title>Olan/Olan</title>
            <description>Maintenance period. Olanzapine Oral tablet, 5 mg/day to 20 mg/day, Once daily (Olanzapine in the acute and continuation period)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Recurrence of Manic Symptoms Associated With Bipolar I Disorder</title>
          <description>This was the key secondary efficacy end-point. Pali/Pali and Pali/Placebo were compared with each other with respect to time to recurrence of manic symptoms. The criterias used for this analysis were similar to criterias used for primary analysis.</description>
          <population>Intent-to-treat analysis set in MA phase, which included participants who entered the MA phase and took at least 1 dose of study medication.</population>
          <units>Days</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="144"/>
                <count group_id="O4" value="146"/>
                <count group_id="O5" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>25% Quantile of Time to Recurrence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="194.0" lower_limit="125.0" upper_limit="283.0"/>
                    <measurement group_id="O4" value="498.0" lower_limit="294.0" upper_limit="813.0"/>
                    <measurement group_id="O5" value="NA" lower_limit="595.0">There were 11% of the subjects in the Olan/Olan group who reported recurrence of manic symptoms. Hence 25% quartile of time to recurrence was not observed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median Time to Recurrence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="550.0" lower_limit="419.0" upper_limit="878"/>
                    <measurement group_id="O4" value="NA" lower_limit="813">There were 21% of the subjects in the Pali/Pali group who reported recurrence of manic symptoms. Hence median time to recurrence was not observed.</measurement>
                    <measurement group_id="O5" value="NA">There were 11% of the subjects in the Olan/Olan group who reported recurrence of manic symptoms. Hence median time to recurrence was not observed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At the time of interim analysis of the primary efficacy endpoint, the proportion of recurrence of manic symptoms was 81.9% of the number of recurrence of manic symptoms at final analysis. A flexible group-sequential approach was adopted. The general family of alpha spending function based on the rho-family with rho=2.5 at overall type I error of 0.025 (1-sided) was employed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The two treatment groups were compared using a weighted z-statistic based on rho-family of alpha spending function at information fraction of 81.9% at interim analysis analysis (rho=2.5) at 0.025 (1-sided) level. One-sided alpha at final was 0.0198.</p_value_desc>
            <method>Weighted z-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Recurrence of Depressive Symptoms Associated With Bipolar I Disorder</title>
        <description>Pali/Pali and Pali/Placebo were compared with each other with respect to time to recurrence of depressive symptoms. The criterias used for this analysis were similar to criterias used for primary analysis.</description>
        <time_frame>Date of randomization into the maintenance phase until the first occurrence of recurrence of depressive symptoms or discontinuation from the study, assessed over a period of 41 months.</time_frame>
        <population>Intent-to-treat analysis set in MA period, which included participants who entered the maintenance phase and took at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone ER</title>
            <description>Acute and continuation period. Paliperidone ER: Oral tablet, 3 mg/day to 12 mg/day, Once daily.</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>Acute and continuation period. Olanzapine: Oral tablet, 5 mg/day to 20 mg/day, Once daily.</description>
          </group>
          <group group_id="O3">
            <title>Pali/Placebo</title>
            <description>Maintenance period. Placebo (Paliperidone in the acute and continuation period).</description>
          </group>
          <group group_id="O4">
            <title>Pali/Pali</title>
            <description>Maintenance period. Paliperidone ER: Oral tablet, 3 mg/day to 12 mg/day, Once daily (Paliperidone in the acute and continuation period)</description>
          </group>
          <group group_id="O5">
            <title>Olan/Olan</title>
            <description>Maintenance period. Olanzapine Oral tablet, 5 mg/day to 20 mg/day, Once daily (Olanzapine in the acute and continuation period)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Recurrence of Depressive Symptoms Associated With Bipolar I Disorder</title>
          <description>Pali/Pali and Pali/Placebo were compared with each other with respect to time to recurrence of depressive symptoms. The criterias used for this analysis were similar to criterias used for primary analysis.</description>
          <population>Intent-to-treat analysis set in MA period, which included participants who entered the maintenance phase and took at least 1 dose of study medication.</population>
          <units>Days</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="144"/>
                <count group_id="O4" value="146"/>
                <count group_id="O5" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="503.0" lower_limit="203.0">There were 18% of the participants in the Pali/Placebo group who reported recurrence of depressive symptoms.</measurement>
                    <measurement group_id="O4" value="448.0" lower_limit="170.0" upper_limit="750.0"/>
                    <measurement group_id="O5" value="NA" lower_limit="651.0">There were 12% of the participants in the Olan/Olan group who reported recurrence of depressive symptoms. Hence the 25% quartile of the time to recurrence of depressive symptoms was not observed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
            <estimate_desc>Hazard ratio was estimated with Pali/Placebo in the numerator and Pali/Pali in the denominator</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Young Mania Rating Scale (YMRS): Change From Baseline</title>
        <description>This is method by which condition of patient suffering with mania is checked. In this scale patient's condition is assessed using 11 items. A severity rating is assigned to each of 11 items based on the how subject feels of his or her condition and the physicians observation of patients behavior. The range of the scale is 0 to 60. A higher score indicates a more severe condition. Change from baseline (Day 105) in the double‑blind maintenance phase to the last postbaseline assessment.</description>
        <time_frame>From 1st randomization into acute phase to end of acute/continuation phase (ie, up to 15 weeks after 1st randomization), or from randomization into maintenance (MA) phase to the end of MA phase (ie, up to 175 weeks (or 41 months) after 2nd randomization).</time_frame>
        <population>Intent-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone ER</title>
            <description>Acute and continuation period. Paliperidone ER: Oral tablet, 3 mg/day to 12 mg/day, Once daily.</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>Acute and continuation period. Olanzapine: Oral tablet, 5 mg/day to 20 mg/day, Once daily.</description>
          </group>
          <group group_id="O3">
            <title>Pali/Placebo</title>
            <description>Maintenance period. Placebo (Paliperidone in the acute and continuation period).</description>
          </group>
          <group group_id="O4">
            <title>Pali/Pali</title>
            <description>Maintenance period. Paliperidone ER: Oral tablet, 3 mg/day to 12 mg/day, Once daily (Paliperidone in the acute and continuation period)</description>
          </group>
          <group group_id="O5">
            <title>Olan/Olan</title>
            <description>Maintenance period. Olanzapine Oral tablet, 5 mg/day to 20 mg/day, Once daily (Olanzapine in the acute and continuation period)</description>
          </group>
        </group_list>
        <measure>
          <title>Young Mania Rating Scale (YMRS): Change From Baseline</title>
          <description>This is method by which condition of patient suffering with mania is checked. In this scale patient's condition is assessed using 11 items. A severity rating is assigned to each of 11 items based on the how subject feels of his or her condition and the physicians observation of patients behavior. The range of the scale is 0 to 60. A higher score indicates a more severe condition. Change from baseline (Day 105) in the double‑blind maintenance phase to the last postbaseline assessment.</description>
          <population>Intent-to-Treat</population>
          <units>Scores on the scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="602"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="143"/>
                <count group_id="O4" value="144"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.2" spread="11.23"/>
                    <measurement group_id="O2" value="-19.3" spread="10.25"/>
                    <measurement group_id="O3" value="9.0" spread="11.78"/>
                    <measurement group_id="O4" value="4.2" spread="9.33"/>
                    <measurement group_id="O5" value="1.3" spread="6.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline (Maintenance Phase) to Endpoint (Maintenance Phase)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment group (Pali/Pali, Pali/Placebo) and country as factors with baseline value as covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.92</ci_lower_limit>
            <ci_upper_limit>-1.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Montgomery-Asberg Depression Rating Scale (MADRS)</title>
        <description>The MADRS consists of 10 items covering all the important complaints which patient with depression have (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts). Item is scored from 0 (normal) to 6 (severe). Total score (0 to 60) is calculated by adding the scores of all 10 items. A higher score represents a more severe condition. Negative Change in Score Indicates Improvement.</description>
        <time_frame>From 1st randomization into acute phase to end of acute/continuation phase (ie, up to 15 weeks after 1st randomization), or from randomization into maintenance (MA) phase to the end of MA phase (ie, up to 175 weeks (or 41 months) after 2nd randomization).</time_frame>
        <population>Intent-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone ER</title>
            <description>Acute and continuation period. Paliperidone ER: Oral tablet, 3 mg/day to 12 mg/day, Once daily.</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>Acute and continuation period. Olanzapine: Oral tablet, 5 mg/day to 20 mg/day, Once daily.</description>
          </group>
          <group group_id="O3">
            <title>Pali/Placebo</title>
            <description>Maintenance period. Placebo (Paliperidone in the acute and continuation period).</description>
          </group>
          <group group_id="O4">
            <title>Pali/Pali</title>
            <description>Maintenance period. Paliperidone ER: Oral tablet, 3 mg/day to 12 mg/day, Once daily (Paliperidone in the acute and continuation period)</description>
          </group>
          <group group_id="O5">
            <title>Olan/Olan</title>
            <description>Maintenance period. Olanzapine Oral tablet, 5 mg/day to 20 mg/day, Once daily (Olanzapine in the acute and continuation period)</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery-Asberg Depression Rating Scale (MADRS)</title>
          <description>The MADRS consists of 10 items covering all the important complaints which patient with depression have (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts). Item is scored from 0 (normal) to 6 (severe). Total score (0 to 60) is calculated by adding the scores of all 10 items. A higher score represents a more severe condition. Negative Change in Score Indicates Improvement.</description>
          <population>Intent-to-Treat</population>
          <units>Scores on the scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="143"/>
                <count group_id="O4" value="144"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="8.21"/>
                    <measurement group_id="O2" value="-2.7" spread="7.82"/>
                    <measurement group_id="O3" value="6.0" spread="9.16"/>
                    <measurement group_id="O4" value="6.1" spread="10.10"/>
                    <measurement group_id="O5" value="2.5" spread="7.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline (Maintenance Phase) to Endpoint (Maintenance Phase)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.763</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA Model with treatment (Pali/Pali, Pali/Placebo) and country as factors with baseline value as covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.87</ci_lower_limit>
            <ci_upper_limit>2.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Global Assessment of Functioning (GAF): Change From Baseline</title>
        <description>This scale is used when the clinical progress of a subject needs to be assessed in global terms, using a single measure. The GAF scale is rated with respect to psychological, social, and occupational functioning at the time of the assessment only. A higher score indicates a better functioning, with an overall range from 1 to 100. Positive Change in Score Indicates Improvement.</description>
        <time_frame>From 1st randomization into acute phase to end of acute/continuation phase (ie, up to 15 weeks after 1st randomization), or from randomization into maintenance (MA) phase to the end of MA phase (ie, up to 175 weeks (or 41 months) after 2nd randomization).</time_frame>
        <population>Intent-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone ER</title>
            <description>Acute and continuation period. Paliperidone ER: Oral tablet, 3 mg/day to 12 mg/day, Once daily.</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>Acute and continuation period. Olanzapine: Oral tablet, 5 mg/day to 20 mg/day, Once daily.</description>
          </group>
          <group group_id="O3">
            <title>Pali/Placebo</title>
            <description>Maintenance period. Placebo (Paliperidone in the acute and continuation period).</description>
          </group>
          <group group_id="O4">
            <title>Pali/Pali</title>
            <description>Maintenance period. Paliperidone ER: Oral tablet, 3 mg/day to 12 mg/day, Once daily (Paliperidone in the acute and continuation period)</description>
          </group>
          <group group_id="O5">
            <title>Olan/Olan</title>
            <description>Maintenance period. Olanzapine Oral tablet, 5 mg/day to 20 mg/day, Once daily (Olanzapine in the acute and continuation period)</description>
          </group>
        </group_list>
        <measure>
          <title>Global Assessment of Functioning (GAF): Change From Baseline</title>
          <description>This scale is used when the clinical progress of a subject needs to be assessed in global terms, using a single measure. The GAF scale is rated with respect to psychological, social, and occupational functioning at the time of the assessment only. A higher score indicates a better functioning, with an overall range from 1 to 100. Positive Change in Score Indicates Improvement.</description>
          <population>Intent-to-Treat</population>
          <units>Scores on the scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="575"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="131"/>
                <count group_id="O4" value="135"/>
                <count group_id="O5" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6" spread="17.38"/>
                    <measurement group_id="O2" value="20.8" spread="18.26"/>
                    <measurement group_id="O3" value="-15.2" spread="20.93"/>
                    <measurement group_id="O4" value="-8.9" spread="17.75"/>
                    <measurement group_id="O5" value="-4.2" spread="13.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline (Maintenance Phase) to Endpoint (Maintenance Phase)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA Model with treatment (Pali/Pali, Pali/Placebo) and country as factors with baseline value as covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.40</ci_lower_limit>
            <ci_upper_limit>10.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinical Global Impression - Bipolar Disorder - Severity of Illness (CGI-BP-S): Change From Baseline</title>
        <description>The CGI-BP-S rating scale is used to rate the severity of bipolar disorder, including both depressed and manic components, on a 7-point scale ranging from 1 (not ill) to 7 (very severely ill). This scale permits a global evaluation of the subject’s bipolar condition at a given time. Negative Change in Score Indicates Improvement.</description>
        <time_frame>From 1st randomization into acute phase to end of acute/continuation phase (ie, up to 15 weeks after 1st randomization), or from randomization into maintenance (MA) phase to the end of MA phase (ie, up to 175 weeks (or 41 months) after 2nd randomization).</time_frame>
        <population>Intent-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone ER</title>
            <description>Acute and continuation period. Paliperidone ER: Oral tablet, 3 mg/day to 12 mg/day, Once daily.</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>Acute and continuation period. Olanzapine: Oral tablet, 5 mg/day to 20 mg/day, Once daily.</description>
          </group>
          <group group_id="O3">
            <title>Pali/Placebo</title>
            <description>Maintenance period. Placebo (Paliperidone in the acute and continuation period).</description>
          </group>
          <group group_id="O4">
            <title>Pali/Pali</title>
            <description>Maintenance period. Paliperidone ER: Oral tablet, 3 mg/day to 12 mg/day, Once daily (Paliperidone in the acute and continuation period)</description>
          </group>
          <group group_id="O5">
            <title>Olan/Olan</title>
            <description>Maintenance period. Olanzapine Oral tablet, 5 mg/day to 20 mg/day, Once daily (Olanzapine in the acute and continuation period)</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression - Bipolar Disorder - Severity of Illness (CGI-BP-S): Change From Baseline</title>
          <description>The CGI-BP-S rating scale is used to rate the severity of bipolar disorder, including both depressed and manic components, on a 7-point scale ranging from 1 (not ill) to 7 (very severely ill). This scale permits a global evaluation of the subject’s bipolar condition at a given time. Negative Change in Score Indicates Improvement.</description>
          <population>Intent-to-Treat</population>
          <units>Scores on the scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="601"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="143"/>
                <count group_id="O4" value="144"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" lower_limit="-6" upper_limit="2"/>
                    <measurement group_id="O2" value="-3" lower_limit="-5" upper_limit="2"/>
                    <measurement group_id="O3" value="2" lower_limit="-1" upper_limit="6"/>
                    <measurement group_id="O4" value="0" lower_limit="-2" upper_limit="5"/>
                    <measurement group_id="O5" value="0" lower_limit="-1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline (Maintenance Phase) to Endpoint (Maintenance Phase)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA Model on ranks with treatment (Pali/Pali, Pali/Placebo) and country as factors with baseline value as covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Paliperidone ER</title>
          <description>Acute and continuation period. Paliperidone ER: Oral tablet, 3 mg/day to 12 mg/day, Once daily.</description>
        </group>
        <group group_id="E2">
          <title>Olanzapine</title>
          <description>Acute and continuation period. Olanzapine: Oral tablet, 5 mg/day to 20 mg/day, Once daily.</description>
        </group>
        <group group_id="E3">
          <title>Pali/Placebo</title>
          <description>Maintenance period. Placebo (Paliperidone in the acute and continuation period).</description>
        </group>
        <group group_id="E4">
          <title>Pali/Pali</title>
          <description>Maintenance period. Paliperidone ER: Oral tablet, 3 mg/day to 12 mg/day, Once daily (Paliperidone in the acute and continuation period)</description>
        </group>
        <group group_id="E5">
          <title>Olan/Olan</title>
          <description>Maintenance period. Olanzapine Oral tablet, 5 mg/day to 20 mg/day, Once daily (Olanzapine in the acute and continuation period)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>12.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hepatitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypoxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Neuroleptic malignant syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Anger</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Catatonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Depressive symptom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypomania</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pressure of speech</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Self-injurious ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Suicidal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Tachyphrenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Leukoplakia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Breast operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Mastectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nasal operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Sinus operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>12.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="351" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="149"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study employed a randomized withdrawal design, and as such, was enriched for responders to the study drug. Thus, the long-term efficacy demonstrated cannot be extrapolated to a population of patients without prior exposure to paliperidone ER.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinical Leader</name_or_title>
      <organization>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</organization>
      <phone>609-730-2436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

